MedTech Integrates 2020 Track 2


From pills to prosthetics, 3D printing seems to be taking healthcare by storm. Could this be the ultimate personalised healthcare? Are implantable medical devices invasive or ingenious? With more stringent regulation around apps and wearables, can we now trust our healthtech?

Welcome and opening remarks

Martino Picardo, Chairman, Discovery Park

An interview with Ben Newton

Global Head of Oncology Solutions GE Healthcare
Interview conducted by Martino Picardo, Chairman, Discovery Park

Seeing (and enhancing) life in 3D

From pills to prosthetics, 3D printing seems to be taking healthcare by storm. Are we really going to see a printer in every pharmacy or hospital?


MIKE HANNAY | Managing Director Medical Technologies | Innovation Facility


DAN CLARK | Head of Clinical Engineering | Nottingham University Hospital NHS Trust
ASHLEY STRATTON-POWELL | Technical Lead for Orthopaedics, Medicines and Healthcare Products | MHRA
RUSSELL HARRIS | Director of the Future Manufacturing Processes Research Group, School of Mechanical Engineering | University of Leeds
HENRY PINCHBECK | Chief Executive Officer | 3D Lifeprints

Invasive or ingenious

Could implantables be the key to managing chronic diseases?


PARI DATTA | Senior Innovation Consultant | Cambridge Design Partnership


MIKE KARIM | Chief Executive Officer | Oxford Endovascular
CATHERINE DAVIDSON | Head of Business Development – Life Science | MIDAS
RUSS BRADFORD | Co-Founder | Parkinson’s Concierge

Rules are rules

With the regulations around wearables and health apps getting more stringent, are we going to get more trust in tech?


JAMES FRY | Partner | Mills & Reeve


MARK CAMPBELL | Independent Healthtech Consultant
SAM SHAH | Clinical Director | The Ivory Clinic
ARUN PAREKKAT | Digital Analytics Consultant
ROBERTO LIDDI | Senior Vice President, Quality Regulatory and IG Compliance | Sensyne Health
MICHAEL KIPPING | Innovation Lead – Biomedical Catalyst, Health Sector Team | Innovate UK
TINA WILSON | VP, Client Partner – Global Health and Life Sciences | Astound Commerce

Horses for courses

Which investors are right for you and your company? Medtech is a broad church in terms of routes to market, potential business model options and financing requirements. Your financing strategy goes hand-in-hand with your business strategy. What type of financing and which investors at what stage is key to making it all work.


LOUISE JOPLING | Commercial Director | Eastern Academic Health Science Network


REBECCA TODD | Investment Director | Longwall Venture Partners
CHRIS EVANS | Founder | Little Journey
JASON MELLAD | Chief Executive Officer | Start Codon
SUNIL SHAH | Managing Partner, Therapeutics | o2h Ventures
WILL BROOKS | Investment Director | Downing
JIM STEEL | Head of Healthcare & Life Sciences Investment Banking team | Peel Hunt LLP

The Principles of Successful NHS Market Access

Demonstration of the clear benefits of New Technologies to Patients, Providers of Care, Payers of Care and Optimising selling pricing whilst ensuring the technology reached the patients who need it


MICHAEL BRANAGAN-HARRIS | Chief Executive Officer | Device Access UK Ltd


RICHARD MOSS | Director and General Manager, UK & Ireland | SI-Bone
JOHN WEST | Director | Pellere Health
AMANDA HAYHURST  | Founder | Gloucester Road Communications
CHRIS BECKLEY | Market Access & Public Affairs Director | Chiesi Ltd

Virtual drinks reception sponsored by UKRI Innovate UK

Ian Campbell, Interim Chief Executive, Innovate UK